🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against drug-resistant strains of the infection, according to scientists.

An International Health Concern

Gonorrhoea infections are increasing globally, with figures suggesting more than 82 million instances per year. Notably increased rates are observed in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Health officials are increasingly worried about the surge in drug-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the US FDA in recent days for use against gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Results and Global Access

As per data released by a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This places it at an equal footing with the existing first-line therapy, which involves an injection and a pill. The study included hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Doctors directly involved have shared optimism. Having a single-dose, oral treatment like this is hailed as a "critical tool" for public health efforts. This is viewed as essential to reduce the burden of the disease for people and to halt the transmission of extremely resistant gonorrhoea worldwide.